FIGS’s SWOT analysis: medical apparel stock faces valuation test

FIGS, Inc. has emerged as a specialized player in the medical apparel sector, carving out a distinct position within the broader specialty retail landscape. The company’s focus on high-quality healthcare professional attire has generated notable financial momentum through late 2025, though questions about valuation and growth sustainability have surfaced as the company moves through the first half of 2026.

Strong third quarter performance drives momentum

The company delivered a robust third quarter in 2025, with sales figures surpassing market expectations and adjusted EBITDA exceeding consensus estimates. This outperformance stemmed from multiple factors working in concert. Regional sales growth proved particularly strong, with the company demonstrating traction across different geographic markets. The expansion beyond core territories suggests that demand for premium medical apparel extends across diverse healthcare markets.

Gross margin improvement represented another significant contributor to the quarter’s success. The company achieved higher profitability on each unit sold, reflecting either improved pricing power, better cost management, or a favorable shift in product mix. According to the latest data, FIGS maintains an impressive gross profit margin of 66.61%, significantly above industry averages and demonstrating strong pricing power in the medical apparel segment. This margin expansion proved particularly meaningful given the competitive nature of the apparel retail sector, where maintaining pricing discipline while managing input costs presents ongoing challenges.

Operational expense normalization provided additional tailwinds to profitability metrics. The company had previously faced elevated operational costs, but these expenses returned to more sustainable levels during the third quarter. This normalization allowed the improved gross margins to flow through to bottom-line results more effectively, demonstrating operational leverage in the business model.

Guidance revision signals confidence

Following the strong third quarter results, FIGS management revised guidance upward for the fourth quarter of 2025. The company increased both sales and EBITDA projections, signaling confidence that the positive momentum would continue through year-end. This guidance raise suggested that management viewed the third quarter performance as indicative of underlying business strength rather than temporary factors.

The willingness to raise guidance mid-quarter typically reflects visibility into demand trends and operational execution. For FIGS, this move indicated that order flow, inventory management, and cost controls remained on track to deliver results above previous expectations. The guidance adjustment also provided insight into management’s assessment of the healthcare apparel market’s health heading into the traditionally important holiday shopping period.

Market positioning and valuation dynamics

Analysts have maintained a cautious stance on the stock despite operational improvements. The Equal Weight rating assigned to FIGS reflects a balanced view of the company’s prospects relative to the broader specialty retail sector. This neutral positioning suggests that while the company demonstrates operational competence, analysts see limited catalysts for significant outperformance relative to industry peers.

The price target of $9.00 established in late 2025 created an interesting dynamic, as the stock traded above this level at various points. When shares traded at $11.09 in early December 2025, the stock exceeded the analyst target by more than 20 percent. Currently trading at $12.54, the stock has delivered a remarkable 185% return over the past year. Despite the strong performance, InvestingPro analysis suggests FIGS remains undervalued at current levels. The platform offers comprehensive Fair Value analysis and over 15 additional ProTips for FIGS subscribers, providing deeper insights into the company’s valuation dynamics.

By April 2026, analysts noted incremental improvements in growth rates compared to previous estimates, though the absence of a specific price target indicated continued uncertainty about the appropriate valuation framework. The Market Perform rating assigned at that time reinforced the view that FIGS represented neither a compelling value opportunity nor an obvious candidate for underperformance.

Medical apparel sector dynamics

FIGS operates within a specialized niche of the broader apparel industry, focusing exclusively on healthcare professionals. This focus provides both advantages and constraints. The medical apparel market benefits from relatively stable demand tied to healthcare employment rather than discretionary consumer spending patterns. Healthcare workers require functional, professional attire regardless of broader economic conditions, providing a degree of demand stability.

The company’s participation in industry conferences, including representation by senior executives at the Barclays Eat, Sleep, Play, Shop Conference, demonstrates active engagement with the investment community. These forums provide opportunities to communicate strategic priorities and address investor questions about market positioning and growth initiatives.

The specialty retail apparel and footwear sector faces ongoing challenges from evolving consumer preferences, e-commerce competition, and supply chain complexities. FIGS must navigate these broader industry headwinds while capitalizing on the specific characteristics of the medical apparel market. The company’s ability to maintain margin expansion while growing sales suggests some success in managing these competing pressures.

Financial metrics and earnings trajectory

The company’s estimated earnings per share trajectory shows modest growth expectations. Fiscal year one estimates of $0.12 per share rising to $0.16 in fiscal year two represent approximately 33 percent growth. This earnings progression reflects expectations for continued operational leverage as the company scales revenue while managing costs.

The market capitalization of $2.09 billion positions FIGS as a mid-sized specialty retailer. This scale provides sufficient resources for marketing, technology investments, and supply chain management while maintaining the agility to respond to market opportunities more quickly than larger competitors.

Bear Case

Can FIGS maintain premium valuation without accelerating growth?

The stock’s trading history above analyst price targets raises questions about valuation sustainability. When shares exceed analyst targets by significant margins, the market has typically priced in optimistic scenarios that may not materialize. For FIGS, the challenge lies in delivering growth and profitability improvements that justify premium valuations relative to both the price target and peer multiples.

The incremental growth improvements noted by analysts in April 2026 suggest progress, but the characterization as "incremental" rather than transformational indicates measured expectations. If revenue growth rates remain in modest single digits or low double digits, the company may struggle to support valuations that imply more aggressive expansion. The medical apparel market, while stable, has finite size constraints that could limit FIGS’s addressable opportunity as the company gains market share.

Will operational expense normalization pressure future margin expansion?

The third quarter 2025 results benefited significantly from operational expenses returning to normal levels after a period of elevation. This normalization provided a one-time boost to profitability metrics that may prove difficult to replicate. Future margin improvements would need to come from either continued gross margin expansion or further operational efficiencies, both of which face natural limits.

Gross margin improvement can result from pricing increases, cost reductions, or favorable product mix shifts. Each of these levers faces constraints. Pricing power depends on competitive dynamics and customer willingness to pay premiums for FIGS products. Cost reductions require ongoing supply chain optimization that becomes progressively harder to achieve. Product mix improvements depend on successfully shifting customers toward higher-margin items, which may not align with customer preferences or market demand.

Bull Case

Can regional expansion drive sustained revenue acceleration?

The strong regional sales growth demonstrated in the third quarter of 2025 suggests FIGS has successfully expanded beyond its initial core markets. If the company can replicate this success in additional geographies, both domestically and internationally, significant revenue runway remains available. Healthcare employment continues growing in many markets, providing an expanding customer base for medical apparel.

The company’s specialized focus on healthcare professionals creates opportunities for targeted marketing and product development that generalist apparel retailers cannot easily replicate. FIGS can develop deep relationships with healthcare institutions, professional organizations, and individual practitioners. These relationships can translate into recurring revenue streams as healthcare workers replace worn items and purchase additional products for different clinical settings.

International expansion represents a particularly compelling opportunity. Healthcare systems worldwide employ millions of professionals who require functional, professional attire. If FIGS can adapt its product offerings and marketing approach to different international markets, the addressable market expands substantially beyond the domestic opportunity. Success in even a few international markets could drive years of revenue growth.

Will margin improvements translate to stronger earnings growth than expected?

The gross margin expansion achieved in the third quarter of 2025 demonstrates FIGS’s ability to improve unit economics. If the company can sustain or further expand these margins, earnings growth could exceed current analyst estimates. The combination of revenue growth and margin expansion creates operating leverage that can drive disproportionate earnings increases.

Several factors could support continued margin improvement. Scale economies in manufacturing and logistics typically emerge as companies grow volume. FIGS may negotiate better terms with suppliers, optimize shipping routes, and reduce per-unit overhead costs. Direct-to-consumer sales channels, which typically carry higher margins than wholesale distribution, could represent a growing percentage of revenue. Technology investments in inventory management and demand forecasting can reduce markdowns and improve full-price selling.

The normalized operational expense base provides a platform for leverage. If FIGS grows revenue while maintaining disciplined cost controls, incremental sales can flow through to earnings at high rates. This operating leverage could enable the company to exceed the $0.16 fiscal year two earnings estimate, potentially justifying higher valuations and driving stock price appreciation.

SWOT Analysis

Strengths

• Specialized focus on medical apparel market with stable demand characteristics
• Strong third quarter 2025 performance with sales and EBITDA exceeding expectations
• Successful regional expansion demonstrating geographic scalability
• Gross margin expansion indicating improved unit economics
• Normalized operational expense base providing platform for leverage
• Direct relationships with healthcare professional customer base

Weaknesses

• Stock trading above analyst price target suggesting limited upside visibility
• Modest earnings growth trajectory with fiscal year estimates showing measured progression
• Dependence on healthcare sector employment trends
• Limited product category diversification beyond medical apparel
• Uncertain pricing power in competitive apparel market

Opportunities

• International market expansion into healthcare systems worldwide
• Further margin improvement through scale economies and operational efficiencies
• Product line extensions within healthcare professional categories
• Direct-to-consumer channel growth with higher margin potential
• Institutional partnerships with healthcare systems and organizations
• Growing healthcare employment providing expanding customer base

Threats

• Competitive pressure from established apparel brands entering medical segment
• Neutral industry outlook for specialty retail apparel sector
• Valuation concerns if growth rates fail to accelerate
• Supply chain disruptions affecting cost structure and product availability
• Economic pressures on healthcare institutions affecting purchasing budgets
• E-commerce competition from generalist retailers

Analyst Targets

Barclays Capital Inc. - Equal Weight rating with price target of $9.00 - December 5th, 2025

Market Perform rating with no specific price target - April 23rd, 2026

This analysis incorporates information available through April 2026, including financial results from the third quarter of 2025 and analyst perspectives through late April 2026.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on FIGS. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore FIGS’s full potential at InvestingPro.

Should you invest in FIGS right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if FIGS is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate FIGS further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if FIGS appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.